Read the First Edition of The Lens, a new magazine by LSI arrow-icon
Learn More About Abide Therapeutics
Abide Therapeutics
Reports Graph
An approach to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications such as: central nervous system (CNS) disorders, cancer, inflammation & metabolic diseases, viral & bacterial infections, and orphan diseases
Technology/product details
Revenue projections
Capital raised to date
Growth strategy
Competing Startups
More

Get a Demo and See the Full Profile

Get a demo today to see profiles of Spineology plus 6164 other startups.

Trusted By The Companies Pioneering What’s Next